Update on bronchiectasis guidelines. James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK

Similar documents
Bronchiectasis. What is bronchiectasis? What causes bronchiectasis?

National Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008

Outcomes and GRADE Summary of Findings Tables: old and new

Dr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

The management of bronchiectasis in Europe

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Decramer 2014 a &b [21]

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Management of bronchiectasis in adults

Cystic Fibrosis Panel Applications (Dornase Alfa) Contents

Bronchiectasis in Adults - Suspected

Bronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago

Cochrane-GRADE Workshop

A Place For Airway Clearance Therapy In Today s Healthcare Environment

Prof Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital

Chronic Obstructive Pulmonary Disease

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

COPD Treatable. Preventable.

JUERGEN FROEHLICH, JANICE DAHMS, DAVID CIPOLLA,

INHALED ANTIBIOTICS THERAPY IN NON-CF LUNG DISEASE

COPD Bronchiectasis Overlap Syndrome.

A. Service Specifications

RESPIRATORY CARE IN GENERAL PRACTICE

Chronic obstructive lung disease. Dr/Rehab F.Gwada

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Pathway diagrams Annex F

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Bronchiectasis. Introduction. Key points

PANEL KEGAWAT DARURATAN SISTEM PERNAPASAN (SERANGAN ASMA AKUT, PNEUMONIA DAN COPD) dan EDEMA PARU

REFERRAL GUIDELINES RESPIRATORY

Over the last several years various national and

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF

COUGH. Jim Reid University of Otago Medical School Dunedin, New Zealand

BTS Guideline for non-cf Bronchiectasis

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh

COPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer

The FDA Critical Path Initiative

Around-COPD Verona (Italy), January Highlights

Recent advances in diagnosis and management of ABPA. Arindam SR(Pulmonary Medicine)

Guideline for the Diagnosis and Management of COPD

NON-CF BRONCHIECTASIS IN ADULTS

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Understanding the heterogeneity of the disease

C.S. HAWORTH 1, A. WANNER 2, J. FROEHLICH 3, T. O'NEAL 3, A. DAVIS 4, I. GONDA 3, A. O'DONNELL 5

Diagnosis, Treatment and Management of Asthma

Non-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX

NON-CYSTIC FIBROSIS BRONCHIECTASIS

Bronchiectasis it s effects on the NZ population and what we can do to address this

British Thoracic Society Guidelines for Bronchiectasis in adults. Available for public consultation from 13 March 2018 to 16 April 2018

Cystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis

Shared Care Guideline

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

Appendix D Clinical specialist statement template

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)

OPAT FOR INFECTION IN BRONCHIECTASIS

Washington, DC, November 9, 2009 Institute of Medicine

Impact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

Table 1: Guideline data collection

Bronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza)

BRONCHIAL THERMOPLASTY

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

British Guideline on the Management of Asthma

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Organised by : Powered by :

Welcome to the 2 nd World Bronchiectasis Conference

Chronic obstructive pulmonary disease

Evaluation of Patients with Diffuse Bronchiectasis

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines

MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER

Pseudomonas aeruginosa eradication guideline

Clinical Policy Title: Bronchial thermoplasty for severe asthma

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014

ASTHMA. Dr Liz Gamble BRI

Starship Paediatric Respiratory and Sleep Medicine Department Outpatient Referral Criteria General Principles

COPD Research at the University of Maryland School of Maryland

An Update in COPD John Hurst PhD FRCP

Update on management of respiratory symptoms. Dr Farid Bazari Consultant Respiratory Physician Kingston Hospital NHS FT

Objectives. Information proliferation. Guidelines: Evidence or Expert opinion or???? 21/01/2017. Evidence-based clinical decisions

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease

Using Pay-for-Performance to Improve COPD Care MHC64474 SV64474

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

Pulmonary Rehabilitation in COPD-An Important Non-pharmacological Treatment

PCRS-UK briefing document Asthma guidelines. November 2017

Non Cystic Fibrosis Bronchiectasis: How to Proceed?

an inflammation of the bronchial tubes

educating people and transforming lives worldwide

West of Scotland Difficult Asthma Group Statement of Practice

Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network

Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA

Acute Respiratory Infection. Dr Anthony Gibson

COPD and environmental risk factors other than smoking. 14. Summary

Chronic suppurative lung disease in adults

Northumbria Healthcare NHS Foundation Trust. Bronchiectasis. Issued by Respiratory Medicine

Integrated Cardiopulmonary Pharmacology Third Edition

Transcription:

Update on bronchiectasis guidelines James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK

University of Dundee

Bronchiectasis guidelines 2017 2010 2006 2008 2015 2015

Currently valid guidelines SEPAR 2008 Diagnosis and treatment of bronchiectasis British Thoracic Society 2010 Non cystic fibrosis bronchiectasis Australia and New Zealand 2015 Chronic suppurative lung disease and bronchiectasis guidelines

Physiotherapy Key recommendations Physiotherapy once or three times per week for patients producing >30ml per day (strong recommendation, low quality evidence) Patients should be taught airway clearance techniques (grade D recommendation= expert opinion) Airway clearance techniques are recommended and a respiratory physiotherapist advice should be sought

Antibiotics Key recommendations Treatment with prolonged antibiotics for patients with chronic bronchial infection (defined as purulent sputum and positive sputum cultures)- oral or inhaled targeted antibiotic recommended aiming to make the sputum white (strong recommendation, moderate quality evidence) Patients having 3 or more exacerbations per year requiring antibiotic therapy or patients with fewer exacerbations that are causing significant morbidity should be considered for long term antibiotics Macrolides can be considered for 12-24months in those with >3 exacerbations per year or 2 or more hospital admissions in 12 months. Inhaled antibiotics not recommended routinely, only for P. aeruginosa and frequent exacerbations.

Key recommendations Inhaled corticosteroids and bronchodilators Inhaled steroids recommended for patients with bronchial hyperresponsiveness and consider for patients with large sputum volumes. Bronchodilators recommended for patients with bronchial hyperresponsiveness Appropriate to assess patients for airflow obstruction reversibility and to initiate therapy where lung function or symptoms improve Current evidence does not support routine use of inhaled corticosteroids in bronchiectasis outside of asthma Inhaled corticosteroids not recommended except for patients with asthma or COPD Bronchodilators are used on an individual basis

Clinical Guidelines Why do guidelines differ? Factors contributing to guidelines Evidence and methodology Clinical problems and cost effectiveness Expert and patients opinions

Highly limited evidence base Only 3 Grade A recommendations in the 2010 BTS guidelines - Screen for antibody deficiency - Offer active cycle of breathing technique - Recombinant DNAse should not be used

Randomization raises initial quality RCTs: high Observational: low P I C O Outcome Outcome Outcome Outcome Evidence synthesis Critical Critical Important Not Summary of findings & estimate of effect for each outcome High Moderate Low Very low 1. Risk of bias 2. Inconsistency O3. Indirectness OO4. Imprecision OOO5. Publication bias Grade down Grade up 1. Large effect 2. Dose response 3. Opposing bias & Confounders Recommendation Grade recommendations (Evidence to Recommendation) For or against (direction) Strong or conditional/weak (strength) By considering balance of consequences (evidence to recommendations): Quality of evidence Balance benefits/harms Values and preferences Feasibility, equity and acceptability Resource use (if applicable) Guideline Grade overall quality of evidence across outcomes based on lowest quality of critical outcomes Formulate Recommendations ( ) The panel recommends that.should... The panel suggests that.should... The panel suggests to not... The panel recommends to not... Transparency, clear, actionable Research?

ERS bronchiectasis guidelines Will be announced on Sunday 10 th September 2017 in Milan (14.45-16.45) Created using GRADE approach Methodologically rigorous Restrained in scope

Guidelines vs Real Life 80 % tested 60 40 20 EMBARC registry N=7781, 25 countries (Europe only) 0 Immunoglobulins ABPA Sputum for NTM Autoantibodies Bronchoscopy Alpha-1 antitrypsin Functional antibodies cystic fibross PCD

Guidelines are crucial to improving future care for patients with bronchiectasis The current poor evidence base limits strong recommendations The ERS guidelines 2017 will be the first international guidelines using the GRADE approach